STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #295 by analyst upside · 2026-06-27
AYTU
Aytu BioPharma, Inc.
Healthcare · Market Cap $23M · P/E 0x
ANALYST PRICE TARGET
+337.8%
implied upside to consensus target
Current Price $2.17
Consensus Target $9.5
Bull Target $14.5
Bear Target $7.0
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
2
Hold
0
Sell
0
52-Week Low $1.65
52-Week High $3.07
YTD Return -21.7%
FUNDAMENTALS
Market Cap $23M
P/E Ratio (TTM) N/A
Forward P/E -28.9x
EPS (TTM) $-4.61
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $57M
Profit Margin -60.2%
52-WEEK RANGE
52-Week Low $1.65
52-Week High $3.07
Current Price $2.17
Bear Target $7.0
Bull Target $14.5
● Now $2.17 ● Target $9.5
TRADING DATA
Avg Volume 40K
YTD Return -21.7%
Analyst Count 3
Consensus Buy
Upside to Target +337.8%
Last Updated 2026-06-27

ANALYST SUMMARY

Aytu BioPharma, Inc. (AYTU) is currently trading at $2.17 with a Wall Street consensus price target of $9.5, implying potential upside of 337.8% over the next 12 months. 3 analysts currently cover AYTU, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $14.5, while the most cautious has a target of $7.0.

AYTU operates in the Healthcare sector with a market capitalisation of $23M. The stock is down 21.7% year-to-date and is currently trading near the lower end of its 52-week range of $1.65 – $3.07.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for AYTU, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Ascendiant Capital — Reiterated
Buy → Buy 2026-06-11 Building track record
Ascendiant Capital — Reiterated
Buy → Buy 2025-12-10 Building track record
Maxim Group — Reiterated
Buy → Buy 2025-09-25 28% win rate (40 calls)
Ascendiant Capital — Reiterated
Buy → Buy 2025-09-25 Building track record
Lake Street ● Initiated
Buy 2025-07-01 27% win rate (11 calls)
Ascendiant Capital ● Initiated
Buy 2025-06-30 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
38
out of 100
Coverage depth
11/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →